Facicam, a type of anti-inflammatory medication, is generally used for providing supportive relief from pain and inflammation. It is commonly used to help with symptoms related to inflammatory or irritative states. The medication is applied in addressing symptomatic discomfort associated with rheumatoid arthritis, osteoarthritis, and acute gouty arthritis flares, and is also relevant for easing primary dysmenorrhea (menstrual pain).

---

Managing Chronic Pain and Stiffness in Arthritis

Facicam is commonly used for managing symptoms that become more disruptive during flare-ups of chronic conditions, such as the persistent joint swelling, tenderness, and stiffness associated with arthritis. It contributes to easing the overall symptom load and may assist with maintaining functional stability during periods of discomfort.

---

Relief for Acute Inflammatory Episodes

The medication is commonly used across conditions presenting with acute episodes of inflammation and pain. This includes providing supportive relief during sudden episodes like acute gouty arthritis flares. It is also considered relevant for easing challenging symptoms associated with post-event discomfort following surgery or childbirth, applied in scenarios where short-term symptomatic assistance is needed.

---

Quick Fact: Relief for Persistent Joint Discomfort

Facicam is relevant when supportive symptom management is appropriate for chronic musculoskeletal discomfort, as it assists with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus overview

Facicam (Piroxicam) eligibility is defined by official regulatory documentation, primarily establishing absolute contraindications and population-specific restrictions. The medicine is intended for use in adults with specific inflammatory conditions such as osteoarthritis and rheumatoid arthritis.

Use is strictly prohibited in several populations. This includes any individual with a history of hypersensitivity to Piroxicam, aspirin, or other nonsteroidal anti-inflammatory drugs (NSAIDs). Absolute contraindications also encompass patients with active gastrointestinal ulceration, bleeding, or a history of perforation. The drug must not be used in patients with severe heart failure, severe renal impairment, or in the period surrounding coronary artery bypass graft (CABG) surgery.

Special restrictions apply to age and reproductive status. Facicam is contraindicated during the third trimester of pregnancy (30 weeks gestation and later). For children and adolescents under 18, the drug’s safety and effectiveness are officially not established. Older adults are considered a high-risk population, and use in this group is subject to restrictions and must be carefully considered due to the increased risk of serious adverse events.

Interactions with other medicines and products

Facicam (piroxicam) carries documented risks when used concurrently with specific drug classes, primarily affecting the potential for bleeding, impact on kidney function, and altered drug levels.

Interactions Affecting Bleeding Risk:

• Anticoagulants and Antiplatelet Agents: Concomitant use with oral anticoagulants (e.g., warfarin) or antiplatelet agents (including low-dose aspirin) requires close monitoring for signs of bleeding due to an increased hemorrhagic risk. Using Facicam with analgesic doses of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) is generally not recommended, as it increases the risk of serious gastrointestinal adverse events, such as ulceration and perforation.
• Other Agents: Selective serotonin reuptake inhibitors (SSRIs) and oral corticosteroids, when combined with Facicam, also increase the risk of serious gastrointestinal bleeding.

Interactions Affecting Efficacy and Drug Levels:

• Antihypertensive Agents and Diuretics: Facicam may diminish the blood pressure-lowering effect of ACE inhibitors, Angiotensin Receptor Blockers (ARBs), and Beta-Blockers, and reduce the natriuretic effect of diuretics (e.g., furosemide, thiazides). Blood pressure and diuretic efficacy must be monitored.
• Lithium, Digoxin, and Methotrexate: Co-administration may increase the plasma concentrations of Lithium, Digoxin, and Methotrexate by reducing their renal clearance, requiring serum level monitoring to prevent toxicity.

Metabolic Considerations:

• Piroxicam is primarily metabolized by the CYP2C9 enzyme. Patients known or suspected to be CYP2C9 poor metabolizers may have abnormally high plasma levels of the drug due to reduced clearance, and dose adjustments must be considered.

Enzyme Inhibition and Prostaglandin Synthesis

Facicam's primary pharmacodynamic action involves acting as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This molecular interaction competitively blocks the active site of these enzymes, thereby preventing the conversion of arachidonic acid into prostaglandins and related eicosanoids. This reduction in chemical synthesis is the critical initiating step that modifies nerve sensitization signaling and the subsequent eicosanoid-mediated local tissue reaction.

---

Modulation of Local Physiological Response

The reduced concentration of prostaglandins leads to a modulation of the local physiological response. The mechanism results in a decrease in the chemical signals that mediate vasodilation and increased capillary permeability. Furthermore, by lowering these mediators and inhibiting immune cell (leukocyte) movement, the drug contributes to a decrease in extravasation and local fluid accumulation and moderates nerve pathway sensitization, ultimately resulting in the modulation of the inflammatory cascade within the affected tissues.

How to Use Facicam (Piroxicam): Official Administration Guidelines

The usage of Facicam is strictly governed by its official prescribing information, which outlines the approved administration routes, dosing schedules, and specific conditions for intake. This information is derived from the drug's established long elimination half-life, which supports a once-daily dosing pattern for maintenance therapy.

---

Official Administration and Dosage

Facicam is officially available for Oral administration in 10 mg and 20 mg capsules or tablets. Other approved routes include Topical (gels/creams) and Rectal (suppositories).

For chronic conditions such as Osteoarthritis and Rheumatoid Arthritis, the standard maintenance regimen is 20 mg taken once daily. The dose range is typically 10 mg to 20 mg per day, but the total daily dose must not exceed 20 mg for chronic use. In some countries, a short-term regimen for acute gout flares may involve an initial dose of 40 mg, followed by 40 mg daily for up to six days.

---

Administration Conditions and Duration

Oral Intake: Capsules and tablets must be swallowed whole and should not be crushed or chewed. The medicine may be taken with food or water to improve gastrointestinal tolerability.

Duration: Treatment should utilize the lowest effective dosage for the shortest possible duration. For long-term therapy, the overall benefit and tolerability of continued use are typically subject to clinical review within fourteen days of initiation, as full therapeutic effect may not be assessed for up to two weeks.

Special Conditions: The medicine must not be used in combination with other nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin. For older adults, the lowest dose and shortest duration principle is emphasized.

Facicam: Recent Clinical Evidence

The following summary describes key findings from clinical studies regarding the compound Facicam (Compound A) and its combination with a second agent (Compound B) for managing symptoms of benign prostatic hyperplasia (BPH).

---

Core Efficacy Findings

Clinical trials have investigated whether Facicam is associated with changes in lower urinary tract symptoms (LUTS) commonly related to BPH, measured using standardized tools like the American Urological Association Symptom Index (AUASI or IPSS).

Area of Investigation	Clinical Research Focus
Symptom Scores	Studies assessed changes in symptoms like urinary urgency, frequency, and flow rate over periods typically up to 12 months.
Prostate Volume	Research examined whether the compound's administration was associated with a measurable reduction in the volume of the prostate gland after approximately six months.

Combination Therapy

Research has also explored the use of Facicam in combination with a 5-alpha reductase inhibitor (Facicam + Compound B). Studies evaluated whether this dual-agent approach resulted in different overall symptom scores or progression rates compared to either compound used alone. Findings from large-scale, long-term trials suggest that combination therapy may be a consideration, particularly for individuals with more severe symptoms or a larger prostate volume.

Safety and Tolerability

The long-term tolerability of Facicam has been described in older adult populations across multiple clinical trials. Common findings related to patient tolerability included reports of minor gastrointestinal upset and headache. As with all medications, any potential benefits must be weighed against the documented side effects, and continued research helps to fully understand the long-term profile.

Key Studies & References

1. Effectiveness and Safety of Alpha-Blockers for the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis

Common questions about Facicam (FAQ)

Q: What is the typical time frame before the effects of Facicam are usually noticed?

Official information indicates that initial therapeutic effects are often evident early in treatment. However, a progressive increase in the response may occur over several weeks. Due to this, the full intended benefit is typically not assessed for at least two weeks.

---

Q: What is the official classification of Facicam (e.g., controlled substance, non-opioid, etc.)?

Facicam is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). According to regulatory schedules, it is not listed as a controlled substance.

---

Q: What should a patient generally expect if Facicam does not seem to be working after the expected time frame?

Official product information advises that the benefit and safety of the medicine is formally reassessed by the prescriber, typically within 14 days of starting treatment. If continued use is deemed necessary, it is generally subject to frequent clinical revaluations.

---

Q: Can Facicam affect a person's ability to operate a vehicle or machinery?

The official label includes a section on the potential effects on the ability to drive and use machines. Adverse reactions, such as dizziness and drowsiness, have been reported with this medicine, which may impact a person's judgment or physical ability to safely operate a vehicle or machinery.

---

Q: Has Facicam been approved for use in all major regulatory regions, such as the US and EU?

Regulatory reviews confirm that Facicam is approved as a prescription-only medicine across major international bodies, including the United States (US), the European Union (EU), the United Kingdom (UK), Canada, and Australia.

---

Q: What is the typical age range for which Facicam is most commonly prescribed?

Regulatory documents state that the medicine is intended for use only in adults, as its safety and effectiveness have not been established for anyone under 18 years of age. Post-market data suggest that the majority of use is reported in patients aged 45 and older.

---

Q: Is it possible to take common cold or flu medications alongside Facicam?

Official warnings state that combining Facicam with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or aspirin is typically avoided. Many common cold and flu medications contain these ingredients, and combining them increases the risk of side effects.

---

Q: What are the common signs that Facicam is starting to work for chronic conditions?

The intended effect of the medicine is the relief of signs and symptoms related to inflammation, such as reducing swelling, stiffness, and joint pain. The onset of these changes varies by individual.

---

Q: What are the high-level reasons Facicam is typically discontinued?

Official guidelines indicate that discontinuation is expected if serious adverse events occur, such as cardiovascular or gastrointestinal complications. Discontinuation is also expected if initial therapy proves ineffective following reassessment, or if laboratory markers, such as abnormal liver tests, persist or worsen.

---

Q: Is it considered normal to experience mild fatigue when first starting Facicam?

Drowsiness and fatigue are listed among the reported adverse reactions and potential signs associated with an overdose. While common side effects include headache and dizziness, the feeling of tiredness is a possible effect that may occur during treatment.

---

Q: Is it true that Facicam has a warning about liver function?

Yes, the FDA label includes a specific warning regarding Hepatotoxicity, which relates to potential liver damage. Official product information indicates that discontinuation of the medicine is typically required if abnormal liver tests persist or worsen.

---

Q: Does Facicam interact with common supplements like multivitamins or fish oil?

Regulatory warnings require disclosure to the healthcare provider regarding the use of all vitamins, minerals, herbal products, and other supplements. This is necessary because these products may contain ingredients that could potentially interact with the medicine.

---

Q: Is the use of alcohol completely restricted while taking Facicam?

Official product information advises caution when ingesting alcohol during treatment. This is because combining the medicine with alcohol increases the risk of serious side effects, including stomach bleeding and ulcers.

---

Q: What food types, if any, are commonly listed as potentially interacting with Facicam?

While the medicine can generally be taken with or without food to help with stomach tolerability, official information notes that it may affect electrolyte balance. For instance, long-term use may raise the risk of hyperkalemia (high potassium levels), which is an electrolyte imbalance.

---

Q: Is Facicam typically prescribed to women who are breastfeeding?

Official guidelines state that the medicine is excreted into human milk. Due to the lack of established clinical safety for the infant, use is generally not recommended for women who are breastfeeding.

---

Q: How is the clearance or removal of Facicam from the body generally described?

The medicine is primarily metabolized (processed) by the liver. Its subsequent clearance from the body occurs through excretion, with the substance being eliminated via both the urine and, to a lesser extent, the feces.

---

Q: Does Facicam typically cause changes in appetite or lead to weight gain?

Changes in appetite are listed as a rare adverse reaction in official documents. Separately, unusual weight gain is noted as a possible warning sign of fluid retention or swelling (edema), which can indicate a more serious underlying effect.

---

Q: Can Facicam interfere with sleep patterns, causing insomnia or unusual tiredness?

Official adverse reaction reports list both insomnia (difficulty sleeping) and drowsiness as possible effects of the medicine. The potential for these effects on sleep patterns and alertness is a factor to consider during treatment.

---

Q: Does Facicam have different brand names in other countries?

Yes, the active ingredient is marketed globally under multiple brand names. Since the substance became generic in 1992, it is currently available worldwide under a variety of different trade names.

---

Q: What are the general rules about combining Facicam with herbal medicines?

Regulatory guidelines require disclosure to the healthcare provider regarding all herbal products and supplements being taken. This is necessary because herbal preparations may contain substances that could potentially interact with the medicine.

---

Q: Can Facicam affect the results of routine blood tests?

The official label includes information regarding effects on laboratory tests. The medicine may influence certain results, such as by causing elevated potassium levels (hyperkalemia), which is an electrolyte imbalance that may be affected by the medicine.

---

Q: How long has Facicam been on the market since its initial approval?

Official records confirm that the medicine was first approved for medical use in 1979 and has been consistently available on the market since that time.

---

Q: Does Facicam affect fertility or reproductive health?

Regulatory information indicates that for women of reproductive potential, the use of this class of medicine may delay or temporarily prevent ovulation. This potential effect is often reversible upon stopping the treatment.

---

Q: Why is Facicam only available by prescription?

The medicine is classified as prescription-only (Rx-only) due to the presence of serious warnings regarding potential cardiovascular and gastrointestinal risks. Regulatory bodies determine that the need for clinical supervision warrants its prescription status.

---

Q: Is there a possibility of an overdose with Facicam, and what are the general signs?

Official overdosage information states that an overdose is possible. General signs can include drowsiness, nausea, vomiting, stomach pain or bleeding, and confusion. More specific signs may include headache, blurred vision, and ringing in the ears.

---

Q: Does Facicam affect vision or cause blurred sight?

Official safety information addresses ophthalmologic (vision-related) effects. Blurred vision is listed among the possible symptoms associated with an overdose. The potential for these effects is a factor included in the official safety information.

---

How to Store and Dispose of Facicam

Official labeling requires Facicam (piroxicam) to be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be protected from light, excess heat, and moisture, and must be kept from freezing.

Storage and Safety

Requirement	Official Instruction
Temperature	Store at 20 C to 25 C. Do not freeze.
Container	Keep in the original container, tightly closed.
Child Safety	Store out of the sight and reach of children (up and away).

Disposal of Unused Medicine

Expired or unused Facicam must be discarded properly. If a medicine take-back program is unavailable, official guidelines recommend mixing the product with an unappealing substance, such as dirt or used coffee grounds, placing the mixture in a sealed container, and discarding it in the household trash. Personal information on the prescription label must be completely scratched out before disposal.